Exenatide is a GLP-1 receptor agonist. It is filed in this library under hormones & metabolism, a navigation topic rather than a statement of where it acts. As a regulatory matter it was approved by the FDA but is no longer marketed in the United States.
Regulatory status
Exenatide was approved by the FDA, but the product is no longer marketed in the United States.
An approval that has been discontinued is not the same as a drug you can obtain today.
From the FDA label
is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • BYETTA contains exenatide. Coadministration with other exenatide-containing products is not recommended. BYETTA (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.Quoted from the FDA-approved prescribing information
The evidence
4 sources on Exenatide published between 2012 and 2022, each resolved to its journal of record. Titles are listed so you can judge the evidence rather than take a summary on trust.
Nearby
Before any compound, the useful question is what your bloodwork already says. The OPTML Score reads a full panel against optimal ranges.
See the OPTML ScoreEducational reference only. This page explains what has been published about Exenatide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.
Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.
All 150 peptides